Arbutus Biopharma Corp Forecasted to Earn FY2019 Earnings of ($1.55) Per Share (NASDAQ:ABUS)

Share on StockTwits

Arbutus Biopharma Corp (NASDAQ:ABUS) – Research analysts at Wedbush lifted their FY2019 earnings estimates for shares of Arbutus Biopharma in a research report issued to clients and investors on Monday, February 10th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will earn ($1.55) per share for the year, up from their previous forecast of ($1.59). Wedbush also issued estimates for Arbutus Biopharma’s Q4 2019 earnings at ($0.30) EPS, Q1 2020 earnings at ($0.30) EPS, Q2 2020 earnings at ($0.30) EPS, Q3 2020 earnings at ($0.31) EPS, Q4 2020 earnings at ($0.25) EPS, FY2020 earnings at ($1.16) EPS, Q1 2021 earnings at ($0.25) EPS, Q2 2021 earnings at ($0.21) EPS, Q3 2021 earnings at ($0.21) EPS, Q4 2021 earnings at ($0.21) EPS, FY2021 earnings at ($0.89) EPS, FY2022 earnings at ($0.81) EPS and FY2023 earnings at ($0.80) EPS.

A number of other research analysts have also recently weighed in on ABUS. ValuEngine cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, February 6th. JMP Securities raised shares of Arbutus Biopharma from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, February 5th. B. Riley reissued a “buy” rating and set a $6.00 price objective on shares of Arbutus Biopharma in a research note on Monday, February 10th. Finally, Zacks Investment Research raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Arbutus Biopharma has a consensus rating of “Hold” and a consensus target price of $5.69.

Shares of ABUS opened at $3.35 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 10.70 and a quick ratio of 10.70. The firm has a 50 day simple moving average of $2.97 and a 200-day simple moving average of $1.92. Arbutus Biopharma has a 1-year low of $0.82 and a 1-year high of $4.75. The stock has a market cap of $203.73 million, a price-to-earnings ratio of -1.20 and a beta of 2.45.

Hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley grew its stake in Arbutus Biopharma by 66.7% in the 2nd quarter. Morgan Stanley now owns 1,609,886 shares of the biopharmaceutical company’s stock worth $3,349,000 after acquiring an additional 643,955 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Arbutus Biopharma by 710.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 38,789 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 34,005 shares during the period. Millennium Management LLC grew its stake in shares of Arbutus Biopharma by 75.1% during the 3rd quarter. Millennium Management LLC now owns 356,066 shares of the biopharmaceutical company’s stock valued at $543,000 after buying an additional 152,714 shares during the period. Simplex Trading LLC grew its stake in shares of Arbutus Biopharma by 10,628.7% during the 4th quarter. Simplex Trading LLC now owns 43,344 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 42,940 shares during the period. Finally, Secure Asset Management LLC purchased a new stake in shares of Arbutus Biopharma during the 4th quarter valued at $28,000. 30.69% of the stock is owned by hedge funds and other institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Further Reading: What does an equal weight rating mean?

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.